Search Results

You are looking at 51 - 60 of 119 items for :

  • "papillary" x
  • All content x
Clear All
Full access

Victor T.G. Lin, Lisle M. Nabell, Sharon A. Spencer, William R. Carroll, Shuko Harada, and Eddy S. Yang

cancers, including high-grade colorectal neuroendocrine tumors, 22 papillary thyroid carcinoma, 23 and endometrial cancer. 24 To our knowledge, this is the first report of a patient with BRAF -mutated SDC treated with combined BRAF and MEK inhibition

Full access

Pablo Maroto, Georgia Anguera, Juan Maria Roldan-Romero, Maria Apellániz-Ruiz, Ferran Algaba, Jacqueline Boonman, Mark Nellist, Cristina Montero-Conde, Alberto Cascón, Mercedes Robledo, and Cristina Rodríguez-Antona

% of papillary and chromophobe subtypes have mutations in MTOR, TSC1 , or TSC2. 9 – 11 In addition, inactivation of PTEN is frequent in chRCC. Altogether, genomic targeting of the mTOR pathway occurs in 23% of chRCC cases, 11 , 12 suggesting

Full access

Katherine Y. Fan, Avani S. Dholakia, Aaron T. Wild, Zheng Su, Amy Hacker-Prietz, Rachit Kumar, Mary Hodgin, Charles C. Hsu, Dung T. Le, Ana De Jesus-Acosta, Luis A. Diaz Jr, Daniel A. Laheru, Ralph H. Hruban, Elliot K. Fishman, Todd D. Brown, Timothy M. Pawlik, Christopher L. Wolfgang, Phuoc T. Tran, and Joseph M. Herman

), borderline resectable/locally advanced (BL), or metastatic (M) pancreatic cancer, or BPD. Diagnoses considered to be benign disease included autoimmune pancreatitis, intraductal papillary mucinous neoplasm, or pancreatic cyst. Exclusion criteria included

Full access

Peter E. Clark, Neeraj Agarwal, Matthew C. Biagioli, Mario A. Eisenberger, Richard E. Greenberg, Harry W. Herr, Brant A. Inman, Deborah A. Kuban, Timothy M. Kuzel, Subodh M. Lele, Jeff Michalski, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Elizabeth R. Plimack, Kamal S. Pohar, Michael P. Porter, Jerome P. Richie, Wade J. Sexton, William U. Shipley, Eric J. Small, Philippe E. Spiess, Donald L. Trump, Geoffrey Wile, Timothy G. Wilson, Mary Dwyer, and Maria Ho

tumor is solid (sessile) or high grade, or suggests invasion into muscle, a CT scan or MRI of the abdomen and pelvis is recommended before the TURBT. Because the results of a CT scan rarely alter the management of tumors with a purely papillary

Full access

Mod C. Chandhanayingyong, Nicholas M. Bernthal, Piti Ungarreevittaya, Scott D. Nelson, Sant P. Chawla, and Arun S. Singh

subsequently confirmed with the R130Q mutation in her PTEN gene. In 2008, she had a complete hysterectomy with salpingo-oophorectomy for uterine fibroids, and in 2009 she had a complete thyroidectomy for multicystic adenomatous nodules with focal papillary

Full access

Henry G. Kaplan

present patient. In addition to increased stimulation by RAS, BRAF activity may be increased by the activating BRAF V600E mutation, which has now been identified in several tumor types, including 40% of papillary thyroid cancers, 10% to 65% of

Full access

Srinivas K. Tantravahi, and Theresa L. Werner

% to 7% of uterine tumors. 5 Among epithelial tumors, endometrioid histology is the most common subtype, present in 84% of patients. Poor prognostic subtypes, including papillary serous and clear cell carcinomas, represent the other 6%. 6 Risk factors

Full access

Amanda Bennett, Ronald M. Bukowski, Keith Flaherty, J. Cameron Muir, Craig D. Turner, and Sam Donaldson

18th Annual Conference and was joined in a panel discussion by several of her late husband’s physicians. Mr. Foley’s tumor, variously diagnosed as collecting duct carcinoma and papillary renal cell carcinoma, was an incidental finding in 2000

Full access

Letizia Gandolfi, Sarah Adamo, Alessandro Pileri, Alessandro Broccoli, Lisa Argnani, and Pier Luigi Zinzani

BRAF constitutive activation independently of extracellular signals. 15 The BRAF mutation is detected in many malignant diseases, including primary melanoma, hairy cell leukemia, papillary thyroid carcinoma, colorectal cancer, and in approximately

Full access

Keli Turner, Sheelu Varghese, and H. Richard Alexander

illustrate findings that distinguish DMPM from other peritoneal malignancies, whether primary or secondary. Two related primary malignancies of the peritoneum with distinctive characteristics on CT are well-differentiated papillary mesothelioma and